期刊文献+

替罗非班治疗急性心肌梗死患者发生血小板减少症的临床分析 被引量:5

下载PDF
导出
摘要 目的探讨急性心肌梗死患者应用替罗非班期间发生血小板减少症的临床特点、处理及预后。方法 2005年4月至2010年6月,341例接受替罗非班治疗的急性心肌梗死征患者中,发生5例生血小板减少症,发生率为1.47%。5例患者中,4例为男性,年龄45~78岁。1例为女性,年龄为72岁。回顾性分析5例患者的相关临床情况。结果 5例患者发生血小板减少的时间为接受替罗非班治疗后的血小板减少症2~12 h,血小板最低值在(10~81)×109之间,其中重度1例,极重度1例。停用替罗非班24~144 h后血小板计数值恢复正常。其中3例发生出血并发症;无需要输血小板和输红细胞的病例,未发生再梗死及死亡。结论急性心肌梗死患者应用替罗非班过程中可以发生严重的血小板减少症,虽然发生率相对较低,但在应用过程中仍需要加强监测。
出处 《中国实用医药》 2011年第4期176-178,共3页 China Practical Medicine
  • 相关文献

参考文献9

  • 1Stone GW,Moliterno DJ,Bertrand M,et al.Impact of clinical syndrome acuity on the differential response to 2 glycoproteinⅡb/Ⅲa inhibitors in patients undergoing coronary stenting:the TARGET trial.Circulation,2002,105(20):2347-2354.
  • 2Crouch MA,Napp i JM,Cheang KI.GlycoproteinⅡb/Ⅲa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Ann Pharmacother,2003,37(6):860-875.
  • 3Dasgup ta H,B lankenship JC,Wood GC,et al.Thrombocytopenia complicating treatment with intravenous glycoprotein Ⅱb/Ⅲa receptor inhibitors:a pooled analysis.Am Heart J,2000,140:206-211.
  • 4Huxtable LM,TafreshiMJ,Rakkar AN.Frequency and management of thrombocytopenia with the glycop rotein Ⅱb / Ⅲa receptor antagonists.Am J Cardiol,2006,97:4262429.
  • 5Razakjr OA,Tan HC,Yip WL,et al.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.J Interv Cardiol,2005,18:33-37.
  • 6The RESTORE Investigators.Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation,1997,96:1445-1453.
  • 7Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable sign and symptoms(PRISM-PLUS)study investigators.Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl Med,1998,338:1488-1497.
  • 8Berkowitz SD,Sane DC,Sigmon KN,et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization.Evaluation of c7E3 for the Prevention of Ischemic Complications(EPIC)Study Group.J Am Coll Cardiol,1998,32:311-319.
  • 9Bougie DW,W ilker PR,W uitschick ED,et al.Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associatied with antibodies specific for ligand-occupied GP Ⅱb / Ⅲa.Blood,2002,100:2071-2076.

同被引文献66

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部